| Author |
Title |
JournalName |
Year D |
| Click on Column Headers to Re-Sort The Current List |
| Nichols DE, Ilhan M, Long... |
Comparison of Cardiovascular, Hyperthermic, and Toxic Effects of Para-... |
Arch Int de Pharmaco... |
1975 |
| Lopatka JE, Brewerton CN,... |
The protective effects of methysergide, 6-hydroxydopamine and other ag... |
Res Commun Chem Path... |
1976 |
| Ricaurte G, Bryan G, Stra... |
Hallucinogenic amphetamine selectively destroys brain serotonin nerve ... |
Science |
1985 |
| Davis WM, Hatoum HT, Wate... |
Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevan... |
Alcohol Drug Res |
1987 |
| Noggle FT Jr, DeRuiter J,... |
Synthesis, identification, and acute toxicity of some N-alkyl derivati... |
J Assoc Off Anal Che... |
1987 |
| O'Hearn E, Battaglia G, D... |
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDM... |
J Neurosci |
1988 |
| De Souza EB, Battaglia G,... |
Neurotoxic effect of MDMA on brain serotonin neurons: evidence from ne... |
Ann N Y Acad Sci |
1990 |
| Finnegan KT, Skratt JJ, I... |
The N-methyl-D-aspartate (NMDA) receptor antagonist, dextrorphan, prev... |
Neurosci Lett |
1990 |
| McKenna DJ, Guan XM, Shul... |
3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential eff... |
Pharmacol Biochem Be... |
1991 |
| Olney JW, Labruyere J, Wa... |
NMDA antagonist neurotoxicity: mechanism and prevention |
Science |
1991 |
| Krogsgaard-Larsen P, Hans... |
Naturally-occurring excitatory amino acids as neurotoxins and leads in... |
Toxicol Lett |
1992 |
| Miller DB, O'Callaghan JP |
Environment-, drug- and stress-induced alterations in body temperature... |
J Pharmacol Exp Ther |
1994 |
| O'Callaghan JP, Miller DB |
Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mou... |
J Pharmacol Exp Ther |
1994 |
| Colado MI, Williams JL, G... |
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 me... |
Br J Pharmacol |
1995 |
| Farfel GM, Seiden LS |
Role of hypothermia in the mechanism of protection against serotonergi... |
J Pharmacol Exp Ther |
1995 |
| Hegadoren KM, Baker GB, C... |
Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (... |
J Pharmacol Toxicol ... |
1995 |
| Sprague JE, Nichols DE |
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-meth... |
J Pharmacol Exp Ther |
1995 |
| Miller RT, Serrine SL, Mo... |
Metabolism of 5-(Glutathion-S-yl)-a-methyldopamine Following Intracere... |
Chem Res Toxicol |
1995 |
| Moore KA, Mozayani A, Fie... |
Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methy... |
Forensic Sci Int |
1996 |
| Miller RT, Lau SS, Monks ... |
Effects of intracerebroventricular administration of 5-(glutathion-S-y... |
Chem Res Toxicol |
1996 |
| Miller DB, O'Callaghan JP |
Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interac... |
Ann N Y Acad Sci |
1996 |
| Seiden LS, Sabol KE |
Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possi... |
NIDA Res Monogr |
1996 |
| Wu D, Otton SV, Inaba T, ... |
Interactions of amphetamine analogs with human liver CYP2D6 |
Biochem Pharmacol |
1997 |
| Miller RT, Lau SS, Monks ... |
2,5-bis-(Glutathion-S-yl)-alpha-methyldopamine, a putative metabolite ... |
Eur J Pharmacol |
1997 |
| Tillmann HL, van Pelt FN,... |
Accidental intoxication with methylene dianiline p,p'-diaminodiphenylm... |
J Toxicol Clin Toxic... |
1997 |
| Fitzal S |
[Ketamine and neuroprotection. Clinical outlook] |
Anaesthesist |
1997 |
| Farber NB, Hanslick J, Ki... |
Serotonergic agents that activate 5HT2A receptors prevent NMDA antagon... |
Neuropsychopharmacol... |
1998 |
| Bai F, Lau SS, Monks TJ |
Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine pr... |
Chem Res Toxicol |
1999 |
| Hegadoren KM, Baker GB, B... |
3,4-Methylenedioxy analogues of amphetamine: defining the risks to hum... |
Neurosci Biobehav Re... |
1999 |
| Monks TJ, Ghersi-Egea JF,... |
Symposium overview: the role of glutathione in neuroprotection and neu... |
Toxicol Sci |
1999 |
| de la Torre R, Farré M, O... |
Non-linear pharmacokinetics of MDMA (`ecstasy') in humans |
Br J Clin Pharmacol |
2000 |
| de la Torre R, Farre M, O... |
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans |
Br J Clin Pharmacol |
2000 |
| Gouzoulis-Mayfrank E, Dau... |
Impaired cognitive performance in drug free users of recreational ecst... |
J Neurol Neurosurg P... |
2000 |
| Beitia G, Cobreros A, Sai... |
Ecstasy-induced Toxicity in Rat Liver |
Liver |
2000 |
| Vaiva G, Boss V, Bailly D... |
An 'Accidental' Acute Psychosis with Ecstasy Use |
J Psychoactive Drugs |
2001 |
| Bai F, Jones DC, Lau SS, ... |
Serotonergic Neurotoxicity of 3,4-(+/-)-Methylenedioxyamphetamine and ... |
Chem Res Toxicol |
2001 |
| Mamamoorthy Y, Tyndale R,... |
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic a... |
Pharmacogenetics |
2001 |
| O'Loinsigh ED, Boland G, ... |
Behavioural, hyperthermic and neurotoxic effects of 3,4- methylenediox... |
Prog Neuropsychophar... |
2001 |
| Ramamoorthy Y, Tyndale RF... |
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic a... |
Pharmacogenetics |
2001 |
| Carvalho M, Hawksworth G,... |
Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vi... |
Arch Toxicol |
2002 |
| Jiang XR, Dryhurst G |
Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehyd... |
Chem Res Toxicol |
2002 |
| Gandolfi O, Gaggi R, Volt... |
The activation of serotonin receptors prevents glutamate-induced neuro... |
Pharmacol Res |
2002 |
| Easton N, Fry J, O'Shea E... |
Synthesis, in vitro formation, and behavioural effects of glutathione ... |
Brain Res |
2003 |
| Carvalho M, Milhazes N, R... |
Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopami... |
Arch Toxicol |
2003 |
| Maurer HH, Kraemer T, Spr... |
Chemistry, pharmacology, toxicology, and hepatic metabolism of designe... |
Ther Drug Monit |
2004 |
| Farre M, De La Torre R, O... |
Repeated doses administration of MDMA in humans: pharmacological effec... |
Psychopharmacology (... |
2004 |
| Freudenmann RW, Spitzer M |
The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-eth... |
CNS Drug Rev |
2004 |
| Segura M, Farre M, Pichin... |
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetami... |
Clin Pharmacokinet |
2005 |
| Mechan A, Yuan J, Hatzidi... |
Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in S... |
Neuropsychopharmacol... |
2005 |
| Elliott SP |
MDMA and MDA concentrations in antemortem and postmortem specimens in ... |
J Anal Toxicol |
2005 |
| Crean RD, Davis SA, Von H... |
Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylened... |
Neuroscience |
2006 |
| Capela JP, Macedo C, Bran... |
Neurotoxicity mechanisms of thioether ecstasy metabolites |
Neuroscience |
2007 |
| Camarasa J, Marimon JM, R... |
Memantine prevents the cognitive impairment induced by 3,4-methylenedi... |
Eur J Pharmacol |
2008 |
| Mueller MA, Yuan J, Neudo... |
Further Studies on the Role of Metabolites in MDMA-induced Serotonergi... |
Drug Metab Dispos |
2009 |
| Litjens RP, Brunt TM |
How toxic is ibogaine? |
Clin Toxicol (Phila) |
2016 |
| Pálenícek T, Lhotková E, ... |
Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmaco... |
Prog Neuropsychophar... |
2016 |
| Pinterova N, Horsley RR, ... |
Synthetic Aminoindanes: A Summary of Existing Knowledge |
Front Psychiatry |
2017 |
| Botanas CJ, de la Peña JB... |
Methoxetamine: A foe or friend? |
Neurochem Int |
2019 |
